LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients

被引:147
作者
Lee, SJ
Campos, H
Moye, LA
Sacks, FM
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Univ Texas, Sch Publ Hlth, Houston, TX USA
关键词
apolipoprotein CIII; lipoproteins; coronary heart disease; apolipoprotein E; apolipoprotein B;
D O I
10.1161/01.ATV.0000066131.01313.EB
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. Methods and Results - Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII-) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events ( relative risk [RR] 6.6, P < 0.0001, for 4th versus 1st quartile). LDL CIII+ comprised 10% of total LDL. The main type of LDL, LDL CIII-, was less strongly predictive (RR 2.2, P = 0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P = 0.07; for VLDL CIII-, RR 2.3, P = 0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk. Conclusions - LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.
引用
收藏
页码:853 / 858
页数:6
相关论文
共 35 条
  • [1] Alaupovic P, 1996, METHOD ENZYMOL, V263, P32
  • [2] The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial
    Alaupovic, P
    Mack, WJ
    KnightGibson, C
    Hodis, HN
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (04) : 715 - 722
  • [3] Low-density lipoprotein size, pravastatin treatment, and coronary events
    Campos, H
    Moye, LA
    Glasser, SP
    Stampfer, MJ
    Sacks, FM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (12): : 1468 - 1474
  • [4] Campos H, 2001, J LIPID RES, V42, P1239
  • [5] LOGISTIC DISCRIMINANT-ANALYSIS OF LIPIDS AND APOLIPOPROTEINS IN A POPULATION OF CORONARY-BYPASS PATIENTS AND THE SIGNIFICANCE OF APOLIPOPROTEIN-C-III AND APOLIPOPROTEIN-E
    CHIVOT, L
    MAINARD, F
    BIGOT, E
    BARD, JM
    AUGET, JL
    MADEC, Y
    FRUCHART, JC
    [J]. ATHEROSCLEROSIS, 1990, 82 (03) : 205 - 211
  • [6] Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice - Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
    Ebara, T
    Ramakrishnan, R
    Steiner, G
    Shachter, NS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (11) : 2672 - 2681
  • [7] HYPERTRIGLYCERIDEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE MORTALITY IN SUBJECTS WITH IMPAIRED GLUCOSE-TOLERANCE OR DIABETES - RESULTS FROM THE 11-YEAR FOLLOW-UP OF THE PARIS PROSPECTIVE-STUDY
    FONTBONNE, A
    ESCHWEGE, E
    CAMBIEN, F
    RICHARD, JL
    DUCIMETIERE, P
    THIBULT, N
    WARNET, JM
    CLAUDE, JR
    ROSSELIN, GE
    [J]. DIABETOLOGIA, 1989, 32 (05) : 300 - 304
  • [8] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [9] MORTALITY FROM CORONARY HEART-DISEASE AND STROKE IN RELATION TO DEGREE OF GLYCEMIA - THE WHITEHALL STUDY
    FULLER, JH
    SHIPLEY, MJ
    ROSE, G
    JARRETT, RJ
    KEEN, H
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1983, 287 (6396): : 867 - 870
  • [10] Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes
    Gervaise, N
    Garrigue, MA
    Lasfargues, G
    Lecomte, P
    [J]. DIABETOLOGIA, 2000, 43 (06) : 703 - 708